The study evaluated the overall survival (OS) of SHR-A1904 versus investigator-selected treatment in second-line CLDN18.2-positive advanced GC/GEJC patients
Age 18 to 75 years old (including boundary values)
Volunteer to participate in this clinical study and sign informed consent;
ECOG score 0-1;
Expected survival ≥3 months;
Received anti-tumor therapies such as chemotherapy, radiotherapy, biological therapy, targeted therapy, or immunotherapy within 4 weeks before the first dose of the study
HER2 posotive (IHC 3+ or IHC 2+/ISH +);
Toxicities caused by previous anticancer therapy were not recovered to CTCAE 5.0 Grade≤1;
Individuals with Leptomeningeal metastasis or Active brain metastases;